GGrantIndex
← Leaderboards

Adenosine Therapeutics, Llc

Charlottesville, VA

Compare ↔
$10,872,109
Total funding
23
Grants

Funding over time

peak $2.4M · FY2005–07
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07

Funding mix

By agency

NIH$10,872,109 · 23

By mechanism

R44$6,417,830 · 7
R41$2,432,035 · 10
R43$1,078,691 · 5
R42$943,553 · 1

Investigators at Adenosine Therapeutics, Llc

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Robert D Thompson$4,905,5598 gr2Jayson Michael Rieger$2,043,6254 gr3George Allan Beller$1,956,5292 gr4Robert A Figler$1,624,4453 gr5Ian J Sarembock$1,411,8502 gr6Shannon P Williams$1,276,7723 gr7William M Scheld$633,0553 gr8Ray A Olsson$423,3481 gr

Largest grants

Safety of A2A Adenosine Agonist for Treatment of Sepsis$861,737
R41 · FY2006 · AI
Novel A2A Adenosine Agonists in Vascular Protection$856,793
R44 · FY2004 · HL
Novel A2A Adenosine Agonists in Vascular Protection$811,648
R44 · FY2005 · HL
Antagonists of A2B Adenosine Receptors for Asthma$755,496
R44 · FY2006 · AI
Antagonists of A2B Receptors Improve Insulin Sensitivity$727,289
R44 · FY2004 · DK
Antagonists of A2B Receptors Improve Insulin Sensitivity$697,156
R44 · FY2005 · DK
Antagonists of A2B Adenosine Receptors for Asthma$685,117
R44 · FY2007 · AI
A2a Adenosine Agonists Limit Damage from Infection$516,103
R42 · FY2002 · AI
A2a Adenosine Agonists as Neuroprotectants$471,081
R44 · FY2003 · NS
A2a Adenosine Agonists as Neuroprotectants$457,679
R44 · FY2002 · NS
A2a Adenosine Agonists Limit Damage from Infection$427,450
R42 · FY2003 · AI
Novel Adenosine A2A Agonists in Renal Tissue Protection$423,348
R44 · FY2002 · DK
Safety of Adenosine A2a Agonist for Treatment of Sepsis$415,035
R41 · FY2007 · AI
Novel Adenosine A2A Agonists in Renal Tissue Protection$394,934
R44 · FY2003 · DK
A2A Adenosine Receptor Agonist for the Treatment of IBD$337,360
R43 · FY2004 · DK
A2A Adenosine Receptor Agonist for the Treatment of IBD$335,663
R43 · FY2005 · DK
A2a Adenosine Agonist Cardiac Reperfusion Injury$288,277
R44 · FY2005 · HL
A2A Adenosine Agonist Adjunct for Systemic Anthrax$198,360
R41 · FY2002 · AI
A2a Adenosine Agonists for Diabetic Nephropathy$147,326
R41 · FY2005 · DK
A2a Adenosine Blockers for Parkinson's Disease$139,176
R41 · FY2005 · NS